SCHEMBL14476877

SCHEMBL14476877

NC(=O)c1ccccc1NCc1nncn1Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ HDAC1 Q13547 3/20 0.47
▸ HDAC6 Q9UBN7 3/20 0.47
▸ HDAC8 Q9BY41 2/20 0.47
▸ RPS6KB1 P23443 2/20 0.43
▸ AURKA O14965 1/20 0.41
▸ AURKB Q96GD4 1/20 0.41
▸ SIRT2 Q8IXJ6 2/20 0.41
▸ P2RX7 Q99572 1/20 0.40
▸ CDC7 O00311 1/20 0.39
▸ ROCK2 O75116 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ CLK4 Q9HAZ1 1/20 0.39
▸ MKNK2 Q9HBH9 1/20 0.39
▸ CCR1 P32246 1/20 0.39
▸ CASP1 P29466 1/20 0.39
▸ ABL1 P00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14476260 0.75 P2RX7 (0.49) KDM4EALDH1A1SMN1; SMN2HDAC6P2RX7
SCHEMBL14476740 0.75 P2RX7 (0.49) KDM4EALDH1A1SMN1; SMN2HDAC6P2RX7
SCHEMBL15804431 0.74 CCR1 (0.39) KDM4EALDH1A1HDAC6P2RX7CCR1
SCHEMBL14476258 0.73 P2RX7 (0.50) KDM4EALDH1A1HDAC6P2RX7MKNK2
SCHEMBL14476732 0.71 P2RX7 (0.46) HDAC6P2RX7CCR1
SCHEMBL14476727 0.70 P2RX7 (0.46) P2RX7ADORA3KIF11
SCHEMBL14476263 0.70 P2RX7 (0.47) KDM4EALDH1A1HDAC6P2RX7CCR1
SCHEMBL14476733 0.70 P2RX7 (0.45) KDM4EALDH1A1SMN1; SMN2HDAC6P2RX7
SCHEMBL14476261 0.69 HDAC6 (0.40) KDM4EALDH1A1HDAC6P2RX7CCR1
SCHEMBL14476844 0.67 P2RX7 (0.54) KDM4EALDH1A1HDAC6P2RX7GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140171431-A1 AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) 2014-06-19 — — US disclosed
US-20140171431-A1 AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) 2014-06-19 — — US disclosed
WO-2013000267-A1 AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE 中国科学院上海药物研究所 (CN) 2013-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171431-A1 AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE PLA2G5, LTA4H, PLA2G4A KDM4E 2615/4885ALDH1A1 608/4885SMN1; SMN2 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback